Botanical species · safety record

Geissospermum laeve

The EFSA Compendium of Botanicals holds 8 constituent measurements for Geissospermum laeve. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Geissospermum laeve (Vell.) Miers

8Constituent measurements

0Safety records

6Cited sources

0Licensed products (Canada)

Also recorded as

Geissospermum vellosii Allem.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Bark	Solvent extraction	≤ 0.008 Percent	HPLC-MS/MS	Resolve DOI
Alkaloids	Bark	Solvent extraction	≥ 0.0013 Percent	HPLC-MS/MS	Resolve DOI
Flavopereirine	Bark	Solvent extraction	—	Traditional analytical techniques (wet chemical tests)	Resolve DOI
Geissoschizoline	Unspecified	Solvent extraction	—	Traditional analytical techniques (wet chemical tests)	Resolve DOI
Geissospermine	Bark	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Indole alkaloids	Unspecified	Solvent extraction	—	Traditional analytical techniques (wet chemical tests)	Resolve DOI
Indole alkaloids	Bark	Solvent extraction	9.45 Gram	Traditional analytical techniques (wet chemical tests)	Resolve DOI
Carboline alkaloids	Bark	Solvent extraction	—	Unspecified	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

HUGHES, NA., RAPOPORT, H. FLAVOPEREIRINE, AN ALKALOID FROM GEISSOSPERMUM-VELLOSII. Journal of the american chemical society, 1958, vol. 80, no. 7, p. 1604-1609. DOI
Lima, Joselia A., Costa, Rodrigo Saar., Epifanio, Rosangela A., Castro, Newton G., Rocha, Monica S., Pinto, Angelo C. Geissospermum vellosii stembark Anticholinesterase activity and improvement of scopolamine-induced memory deficits . Pharmacology biochemistry and behavior, 2009, vol. 92, no. 3, p. 508-513. DOI
RAPOPORT, H., MOORE, RE. ALKALOIDS OF GEISSOSPERMUM VELLOSSI - ISOLATION AND STRUCTURE DETERMINATIONS OF VELLOSIMINE, VELLOSIMINOL, AND GEISSOLOSIMINE . Journal of organic chemistry, 1962, vol. 27, no. 9, p. 2981-&. DOI
Bemis, Debra L., Capodice, Jillian L., Desai, Manisha., Katz, Aaron E., Buttyan, Ralph. beta-carboline alkaloid-enriched extract from the amazonian rain forest tree pao pereira suppresses prostate cancer cells. . Journal of the society for integrative oncology, 2009, vol. 7, no. 2, p. 59-65.
Ramos, Alexander E. Fox., Alcover, Charlotte., Evanno, Laurent., Maciuk, Alexandre., Litaudon, Marc., Duplais, Christophe., Bernadat, Guillaume., Gallard, Jean-Francois., Jullian, Jean-Christophe., Mouray, Elisabeth., Grellier, Philippe., Loiseau, Philippe M., Pomel, Sebastien., Poupon, Erwan., Champy, Pierre., Beniddir, Mehdi A. Revisiting Previously Investigated Plants: A Molecular Networking Based Study of Geissospermum laeve . Journal of natural products, 2017, vol. 80, no. 4, p. 1007-1014. DOI
MOORE, RE., RAPOPORT, H. GEISSOVELLINE - NEW ALKALOID FROM GEISSOSPERMUM-VELLOSII. Journal of organic chemistry, 1973, vol. 38, no. 2, p. 215-230. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature